oral HIF-PHD enzyme inhibitor
Ph. III candidate for anemia in CKD
carboxylic acid class of HIF-PHD inhibitors
J. Pharmacol. Exp. Ther.
Akebia Therapeutics, Cambridge, MA
Context. Vadadustat (Akebia Therapeutics) is an oral hypoxia-inducible factor prolyl-4-hydroxylase domain (HIF-PHD) inhibitor being developed for anemia in patients with chronic kidney disease (CKD). HIFs are transcription factors that…